Hindustan Bio Sciences Ltd (HINDBIO) is currently trading at 7.18 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Hindustan Bio Science Ltd is primarily engaged in manufacturing and selling pharmaceutical products, specifically in pharmaceuticals and biotechnology sectors. The company has a diverse operational scope, transitioning from bulk drug sourcing to manufacturing finished dosage forms of pharmaceuticals. Hindustan Bio Science holds DCGI approval for marketing the nephrology product 'Recombinant Human Erythropoietin', branded as 'EPOVIN'. The company boasts world-class facilities for a range of pharmaceutical production, trusted globally by healthcare professionals and patients. Originally involved in the cement industry, the firm has undergone several transformations, reflecting strategic diversification into biotech and pharmaceuticals.

Over the past 52 weeks, Hindustan Bio Sciences Ltd has traded between a low of ₹5.00 and a high of ₹9.92. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Hindustan Bio Sciences Ltd has a market capitalization of approximately 7.34. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Hindustan Bio Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -34.95 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 7.34 Cr, Hindustan Bio Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Hindustan Bio Sciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Hindustan Bio Sciences Ltd is -34.95. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The narrative disclosure cites a board meeting on August 31, 2026, while a corporate actions calendar entry lists a board meeting for reduction of capital on August 30, 2026.